CMR Surgical: Company Profile & Valuation

CMR Surgical is a British medical device company based in Cambridge. It produces a robot-assisted surgery system called Versius. The Versius Surgical Robotic System is a rival of the established Da Vinci Surgical System and claims to be more flexible and versatile, having independent modular arms which are quick and easy to set up. Previously called Cambridge Medical Robotics, it changed name in March 2018.

CMR Surgical today announced that more than 45,000 patients worldwide have now been treated using the Versius Surgical Robotic System, and in the United Kingdom (October 2023) CMR Surgical has 20 NHS hospital partnerships including Guy's and St Thomas' (London), Royal Papworth (Cambridge). The company achieved Unicorn status in 2019, while in 2021 it received a valuation of $3 billion.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds CMR Surgical.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. CMR Surgical availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — CMR Surgical included.

The last valuation is $3B (post-money, Apr 2025).

Lead investors for each round are in the funding timeline.

The closest medical devices & equipment (surgical robotics) peers are on the competitors page.

The routes section explains what is realistically available for a company at this stage.

No. CMR Surgical is a private company; its shares do not trade on a public exchange.